4-aminopyridine for Skin Wound Healing
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorJohn Elfar
About this trial
Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.
The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.
The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.
Eligibility criteria
Qualifiers
Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.
Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.
Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).
Adults subject aged 18-70
Disqualifiers
History of multiple sclerosis, stroke or any other diagnosed neurological disorder
History of hypersensitivity to AMPYRA® or 4-aminopyridine
Current use of aminopyridine medications, including other compounded 4-AP
Suspected renal impairment based on the Choyke questionnaire.
Trial design
Treatments tested in this trial
- 4-Aminopyridine
- Placebo
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
John Elfar
Lead sponsor
University of Arizona
Sponsor institution
Source ClinicalTrials.gov